MediSapiens to Support Terveystalo With Biobank Data Management and Analytics Solutions
HELSINKI, Nov. 15, 2018 /PRNewswire/ -- MediSapiens, a leading developer and provider of genomic, biomedical and health data solutions, has partnered with Terveystalo, a leading private healthcare service provider in Finland, to support their biobank operations with scalable, interactive and secure genomic and clinical data solutions.
MediSapiens is providing Terveystalo with an integral solution to support Terveystalo's biobank, enabling effective use of genomic and clinical data in the daily operations of Finland's largest private biobank. The solution is based on the Genius™ and Biond™ software modules for integral data management and analysis, complimented with the Accurate™ technology for clinical data curation. MediSapiens provides cost- and time-effective solutions to curate and harmonize the legacy clinical data accumulated over the years by Terveystalo, making it significantly easier to apply the data for further analysis and new insights.
Using the Genius data management module, Terveystalo ensures that their biobank operation has a cost-effective and scalable solution in place for the ever-increasing amount of genomic data. The solution provides real-time querying capabilities and together with Biond, the graphical analysis module, it enables combining the genomic data with the vast amounts of clinical data to support Terveystalo researchers in finding new insights to improve the quality of care, healthcare and drug development.
"We are extremely happy to start this project with Terveystalo and to provide the management and analytics solutions for their infrastructure", stated Sami Kilpinen, CEO of MediSapiens. "The new insights that can be found from the clinical and genomic data Terveystalo is working with can in the future improve the quality of healthcare as well as future drug development, and MediSapiens is proud to be supporting this progress."
"We are pleased to find a partner that meets our needs. MediSapiens' data solutions allow us to develop our biobank and take several steps towards being a world-class actor in the field of precision medicine in clinical use", said Lasse Parvinen, Director, Biobank and Clinical Research of Terveystalo
About MediSapiens
MediSapiens Ltd. is a Bio-IT and bioinformatics company specialized in pharmaceutical research and translational genomics, providing life science and biomedical companies and research organizations with tools that help them manage and interpret large genomic, biomedical and clinical data sets. Established in 2009 and based in Helsinki, Finland and Cambridge, Massachusetts, MediSapiens creates intuitive software platforms to manage, integrate, and visualize complex multi-dimensional datasets, such as genomic sequencing data. The company's goal is to drive medicine forward by developing tools that provide scientists with a way to quickly analyze and visualize vast amounts of data and turn it into knowledge that fuels innovation. For further information, please visit www.medisapiens.com
About Terveystalo
Terveystalo is a listed company on the Helsinki Stock Exchange. Terveystalo is the largest healthcare service company in Finland with net sales and network. The company offers versatile primary and secondary health care services for corporate and private customers and the public sector. The nationwide network covers 180 locations across Finland, complemented by 24/7 digital services.
In 2017, Terveystalo had approximately 1.2 million individual customers and approximately 3.3 million doctor visits. Nearly 9,000 healthcare professionals work in Terveystalo, about half of whom are private practitioners. Terveystalo's services carry the Key Flag symbol and the company is a member of the Association for Finnish Work. For further information, please visit www.terveystalo.com
Contact MediSapiens
Sami Kilpinen
CEO, MediSapiens Ltd.
Email: [email protected]
Phone: +358-45-847-8878
MediSapiens
+358-45-847-8878
www.medisapiens.com
[email protected]
This information was brought to you by Cision http://news.cision.com
SOURCE MediSapiens
Share this article